Stylus Medicine
Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures, starting with in vivo CAR-T therapies. The company’s in vivo, non-viral gene integration platform enables precise insertion of therapeutic payloads into the genome without the complexity of ex vivo cell therapy or viral vectors. Stylus' proprietary system is powered by three components: a therapeutic-grade recombinase, a customizable genetic payload, and a targeted lipid nanoparticle (LNP) delivery system. These elements work together to encode therapeutic genes into a genomic safe harbor site with high efficiency and specificity. The company’s platform is versatile and modular, with potential application across oncology, autoimmune, genetic diseases, and beyond. Stylus was co-founded by professors at UC Berkeley and Stanford University, Michael C. Bassik, Ph.D., Ami S. Bhatt, M.D., Ph.D., Lacramioara Bintu, Ph.D., and Patrick Hsu, Ph.D.
